Oncopeptides AB (SE:ONCO)

:ONCO

ONCO

Oncopeptides AB

RESEARCH TOOLSreports

Want to see SE:ONCO full AI Analyst Report?

Oncopeptides AB (ONCO) Price & Analysis

9 Followers

ONCO Stock Chart & Stats

kr4.88

>-kr0.01(-0.39%)

At close: Mar 06 4:00 PM EST

kr4.88

>-kr0.01(-0.39%)

Day’s Range― - ―

52-Week Rangekr1.26 - kr6.19

Previous CloseN/A

Volume80.98K

Average Volume (3M)2.28M

Market Cap

kr686.50M

Enterprise Valuekr336.90M

Total Cash (Recent Filing)kr70.15M

Total Debt (Recent Filing)kr124.23M

Price to Earnings (P/E)―

Beta0.20

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.27

Shares Outstanding387,851,200

10 Day Avg. Volume1,913,694

30 Day Avg. Volume2,284,999

Financial Highlights & Ratios

PEG Ratio0.12

Price to Book (P/B)-18.53

Price to Sales (P/S)15.35

P/FCF Ratio-4.90

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.44

Revenue Forecast (FY)kr150.00M

Bulls Say, Bears Say

Bulls Say

High Gross MarginsExceptional gross margins (92–97%) indicate strong product-level economics and pricing power typical for specialty oncology drugs. This underpins durable per-unit profitability and cash generation potential if operating costs are managed, supporting margin sustainability over time.

Revenue Rebound / Commercial TractionA 39.8% YoY revenue rebound in 2025 signals meaningful commercial traction and accelerating adoption of the company’s offerings. Sustained top-line growth would validate go-to-market execution and support scaling economics, reducing reliance on external funding if maintained.

Focused Oncology FranchiseA clear strategic focus on targeted therapies for multiple myeloma aligns the company with a structurally growing oncology market and creates specialization advantages. A compact workforce (80 employees) suggests lean execution and potential scalable commercialization and R&D efficiency.

Bears Say

Negative Equity / Balance-Sheet RiskShareholders' equity turning negative (-58.9M) is a material capitalization red flag. It limits borrowing capacity, can trigger covenant issues, and makes future financing more dilutive or costly, creating persistent structural risk to financial flexibility and solvency.

Heavy, Persistent Cash BurnOperating and free cash flow of -222.9M in 2025 (and similarly large prior outflows) indicate sustained cash burn. Ongoing negative cash generation necessitates frequent financing, increasing dilution risk and constraining strategic choices unless cash conversion materially improves.

Large Ongoing Operating LossesSubstantial 2025 operating and net losses show entrenched unprofitability despite revenue and high gross margins. Persistent heavy operating costs for commercialization and R&D imply a prolonged path to break-even and sustained funding needs that pressure long-term viability.

Oncopeptides AB News

Oncopeptides seeks EMA approval to move Pepaxti into earlier-line multiple myeloma treatment

Oncopeptides AB ( ($SE:ONCO) ) has shared an announcement. Oncopeptides has submitted a Type II variation application to...

2d ago

Oncopeptides launches German real-world study to bolster Pepaxti’s myeloma profile

Oncopeptides AB ( ($SE:ONCO) ) has shared an announcement. Oncopeptides has enrolled the first patient in its MARINA...

6d ago

Oncopeptides to spotlight Pepaxti data and PDC strategy at EHA 2026

Oncopeptides AB ( ($SE:ONCO) ) has provided an update. Oncopeptides AB will showcase an extensive data package on...

18d ago

Oncopeptides Accelerates CEE Expansion for Pepaxti via Exclusive Salus Distribution Deal

The latest update is out from Oncopeptides AB ( ($SE:ONCO) ). Oncopeptides AB has signed an exclusive agreement...

19d ago

Oncopeptides AGM Backs Incentive Schemes and Expands Capital-Raising Mandate

Oncopeptides AB ( ($SE:ONCO) ) has provided an announcement. Oncopeptides’ Annual General Meeting approved the 2025 annual report,...

24d ago

Oncopeptides’ Pepaxti Shows Strong Phase 2 Data in Myeloma Patients With Renal Impairment

Oncopeptides AB ( ($SE:ONCO) ) has shared an update. Oncopeptides has reported Phase 2 BRIDGE study results showing...

25d ago

Oncopeptides Wins Norwegian Green Light for Pioneering Glioblastoma Trial

The latest update is out from Oncopeptides AB ( ($SE:ONCO) ). Oncopeptides has secured regulatory and ethics approval...

26d ago

Oncopeptides showcases new Pepaxti data to bolster multiple myeloma positioning

Oncopeptides AB ( ($SE:ONCO) ) has shared an announcement. Oncopeptides AB announced new clinical and real-world evidence for...

1M ago

Oncopeptides posts strong Q1 sales growth as Pepaxti momentum builds in Europe

Oncopeptides AB ( ($SE:ONCO) ) has issued an announcement. Oncopeptides reported a strong start to 2026, with first-quarter...

1M ago

Oncopeptides Targets Third-Line Multiple Myeloma Indication to Boost Pepaxti Growth

Oncopeptides AB ( ($SE:ONCO) ) just unveiled an announcement. Oncopeptides plans to seek a Type II variation from...

1M ago

ONCO FAQ

What was Oncopeptides AB’s price range in the past 12 months?

Oncopeptides AB lowest stock price was kr1.25 and its highest was kr6.19 in the past 12 months.

What is Oncopeptides AB’s market cap?

Oncopeptides AB’s market cap is kr686.50M.

When is Oncopeptides AB’s upcoming earnings report date?

Oncopeptides AB’s upcoming earnings report date is Aug 27, 2026 which is in 74 days.

How were Oncopeptides AB’s earnings last quarter?

Oncopeptides AB released its earnings results on May 13, 2026. The company reported -kr0.12 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.12.

Is Oncopeptides AB overvalued?

According to Wall Street analysts Oncopeptides AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Oncopeptides AB pay dividends?

Oncopeptides AB does not currently pay dividends.

What is Oncopeptides AB’s EPS estimate?

Oncopeptides AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Oncopeptides AB have?

Oncopeptides AB has 387,851,200 shares outstanding.

What happened to Oncopeptides AB’s price movement after its last earnings report?

Oncopeptides AB reported an EPS of -kr0.12 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 38.715%.

Which hedge fund is a major shareholder of Oncopeptides AB?

Currently, no hedge funds are holding shares in SE:ONCO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Oncopeptides AB

Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate engineered to address multiple myeloma that has relapsed or become resistant to prior treatments in adult individuals. Founded in 2000, Oncopeptides AB (publ) conducts its main business from Stockholm, Sweden.